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The Banff Digital Pathology Working Group (DPWG) was formed in the time leading up 
to and during the joint American Society for Histocompatibility and Immunogenetics/
Banff Meeting, September 23-27, 2019, held in Pittsburgh, Pennsylvania. At the meet-
ing, the 14th Banff Conference, presentations directly and peripherally related to 
the topic of “digital pathology” were presented; and discussions before, during, and 
after the meeting have resulted in a list of issues to address for the DPWG. Included 
are practice standardization, integrative approaches for study classification, scoring 
of histologic parameters (eg, interstitial fibrosis and tubular atrophy and inflamma-
tion), algorithm classification, and precision diagnosis (eg, molecular pathways and 
therapeutics). Since the meeting, a survey with international participation of mostly 
pathologists (81%) was conducted, showing that whole slide imaging is available at 
the majority of centers (71%) but that artificial intelligence (AI)/machine learning was 
only used in ≈12% of centers, with a wide variety of programs/algorithms employed. 
Digitalization is not just an end in itself. It also is a necessary precondition for AI and 
other approaches. Discussions at the meeting and the survey highlight the unmet need 
for a Banff DPWG and point the way toward future contributions that can be made.
K E Y W O R D S
basic (laboratory) research/science, biopsy, classification systems: Banff classification, clinical 
research/practice, informatics, organ transplantation in general, pathology/histopathology, 
rejection
1  | INTRODUC TION
The American Society for Histocompatibility and Immunogenetics 
(ASHI)/Banff Joint Scientific Meeting was held September 
23-27, 2019, at the David L. Lawrence Convention Center, 
Pittsburgh, Pennsylvania, as a joint meeting between the Banff 
Foundation for Allograft Pathology and the American Society 
for Histocompatibility and Immunogenetics (ASHI). This was the 
14th Banff Conference on Allograft Pathology. The meeting was 
preceded by a video trailer1 by Kim Solez, which highlighted the 
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digital pathology sessions and a video request for comments on a 
digital pathology white paper.2
For purposes of the meeting and this paper, “digital pathology” 
refers to a broad collection of computerized techniques applied to 
pathology, particularly anatomic pathology, including whole slide 
imaging (WSI), algorithms for dedicated morphometric analysis, 
algorithms employing artificial intelligence (AI)/machine learning, 
natural language processing, and novel microscopic techniques 
(eg, multispectral, Fourier transform infrared and other infrared, 
and second harmonic generation imaging), which typically employ 
computerized interfaces.3-7 This definition is in line with a white 
paper from the Digital Pathology Association, which defined 
“digital pathology” as “tools and systems to digitize pathology 
slides and associated meta-data, their storage, review, analysis, 
and enabling infrastructure.”8 Furthermore, “digital pathology” 
can be considered a topic in the larger field of “computational 
pathology.”8,9
The meeting (Premeeting) began with the following presenta-
tions: “Regenerative Medicine: Introduction and Overview—Make 
No Small Plans” (with comments on digital pathology) by Kim 
Solez from the University of Alberta, “Deep Learning and Renal 
Transplant Pathology” by Jesper Kers from Amsterdam, “Single Cells 
and Human Cell Atlas Towards Banff Implementation” by Andrew 
Malone of Washington University in St. Louis, “Banff Interfacing 
AI Natural Language Processing and Virtual Biopsy Systems” by 
Alexandre Loupy from Paris, and a “Discussion and Proposal for a 
Digital Pathology White Paper” by Kim Solez from the University of 
Alberta and Yukako Yagi of Memorial Sloan Kettering Cancer Center 
in New York.
Jesper Kers presented the work by Radboud University Medical 
Center (UMC), Amsterdam UMC, and the Mayo Clinic on deep learn-
ing in the assessment of kidney specimens. With this work, multi-
class semantic segmentation of periodic acid-Schiff–stained kidney 
tissue sections was performed; and this could potentially be useful in 
quantitative studies of kidney specimens. For example, lesion quan-
tifications by their convolutional neural network correlated well with 
the semiquantitative scores by renal pathologists without the issue 
of interobserver variability.10
Andrew Malone presented his work on single-cell transcriptom-
ics and the kidney.11-13 The importance of digital pathology to this 
work is illustrated by the fact that managing the data produced by 
these studies is a major bioinformatics challenge. A recent publica-
tion from Dr Malone's group highlights the utility of these techniques 
in characterizing a case of mixed cellular and antibody-mediated 
rejection. In this case, diverse cell-type populations were charac-
terized, including a diversity of endothelial cells, monocytes, other 
immune cell subtypes, and a variety of native kidney cell types.12 The 
quantitative data that emerge from these studies is quite compatible 
with that which emerges from digital pathology. Both contribute to 
computational biology approaches, and increasing clinical relevance 
will likely emerge.
Alexandre Loupy presented AI research being conducted by 
the Paris Transplant Group. These efforts add to their cutting edge 
work in the development of the iBox prediction system for renal al-
lograft loss14 and modeling allograft rejection injury, particularly an-
tibody-mediated rejection15 and transplant glomerulopathy.16 Their 
current work involves a number of AI efforts, including the use of 
natural language processing to mine discrete data in kidney trans-
plant biopsy reports. He also presented methods for the integration 
of Banff diagnostic scores and diagnoses in systematic algorithms 
that can be executed by computer programs in a manner that ex-
tends upon prior efforts to assemble Banff scoring and diagnoses in 
centralized resources that can be easily accessed by the transplan-
tation community.17
Yukako Yagi presented work on digital 3-dimensional (3D) ap-
proaches and multimodality imaging. Recent work has included 
extensive application of multiplex immunofluorescence and other 
methods to cancer research.18,19 In the field of transplantation pa-
thology, arteries and other anatomic features can be highlighted 
with 3D reconstruction of histological slides containing sequential 
serial sections. For example, “virtual coronary arteriography” of 
chronic allograft vasculopathy can be conducted, and it is likely that 
other disorders can also be structurally examined using these meth-
ods.20,21 Dr Yagi’s group has also demonstrated the cost effective-
ness of digital pathology.22,23
Kim Solez presented concepts underlying the Banff Digital 
Pathology White Paper as well as larger issues. He reviewed the 
results of the video request for comment on the Digital Pathology 
White Paper.2 Digital pathology can serve as a productivity tool 
in a field with projected workforce shortages.24 When viewed as 
a new frontier for research and diagnostic use in the field of an-
atomic pathology, digital pathology could increase interest in the 
field of pathology as a specialty. Medical students are learning 
pathology from digital resources and could find it more appealing 
to contemplate joining a pathology department that is involved in 
the field of digital pathology.25 Pathologists need to be charismatic 
role models emphasizing digital pathology. For trainees, going 
digital is appealing and consistent with the general goal of human 
flourishing.26
It is not necessary that the digital pathology be complete end 
to end, applied uniformly to all specimens, and always used for pri-
mary diagnosis. Most pathology departments are positively inclined 
toward going digital. There is widespread support for at least digital 
archiving, but it seems too rigid to insist that digital pathology al-
ways be used for primary diagnosis, and be applied to every spec-
imen without exceptions, particularly before validation of these 
tests.8,27,28
A working lunch focusing on digital pathology including digital 
liver, kidney, and heart pathology algorithms was also conducted 
by Alton Brad Farris of Emory University in Atlanta and Andrew 
Lesniak of the University of Pittsburgh. After the presentations 
subsequently described in more detail, the working lunch resulted 
in goals for the DPWG that are covered more in the discussion of 
this paper.
Alton Brad Farris described prior Banff studies on renal fibrosis 
assessment, including computerized analysis for the quantification 
     |  3FARRIS et Al.
of renal fibrosis.29 Farris and his colleagues have also quantitated 
renal fibrosis in other studies,30,31 microvessel density,31 and inflam-
mation.32 Similar methods can be applied to other organs to measure 
parameters such as steatosis in the liver.33 Ultimately, whole slide 
imaging can be applied to provide reports that integrate these quan-
titative data into reports that improve patient care.34
Andrew Lesniak described the studies that he, Anthony Demetris, 
and others at the University of Pittsburgh have performed in the 
past and have performed on transplant specimens.35-39 In their labo-
ratory, they utilize multiplex immunostaining to characterize various 
cells, particularly immune cells,36 and use automated image analysis 
to perform “-omics”-type assessment of tissue.38,39
2  | MATERIAL S AND METHODS
2.1 | Survey
A survey was conducted after the 14th Banff Conference on 
Allograft Pathology in 2019 to determine current digital pathology 
practices within the international transplant pathology community. 
Questions were sent via SurveyMonkey40 to both the NEPHROL and 
NEPHNPPT Discussion Groups moderated by Kim Solez and to The 
Transplantation Society mailing list via the Tribune Pulse October 31, 
2019, Issue.
3  | RESULTS
3.1 | Survey of digital pathology routine practice
There were 42 participants in the Survey, and results are given in 
Figures 1-5. Survey respondents consisted of individuals from a va-
riety of professions, with the majority (81%) coming from the field 
of pathology. A number of countries were also represented in the 
survey. Results of the study showed a diverse spectrum of current 
application of WSI and AI implementation. WSI is available at the 
majority of centers (71%). Customized/handcrafted and commer-
cial programs are being implemented, and some groups report using 
multiple programs. Overall, AI/machine learning was only used in 
≈12% of centers.
4  | DISCUSSION
The Banff Digital Pathology Working Group (DPWG) consists of 
a community of individuals willing to collaborate with others and 
support the development and integration of digital pathology into 
clinical practice and research protocols. In the initial efforts, the 
current state has been surveyed. As also detailed in the upcoming 
Banff Meeting Report, the initial goals of the Banff DPWG are also 
detailed in Table 1. As discussed in the working lunch and other 
times at the Banff Conference, future plans include an image bank 
for testing algorithms so that research groups can test their AI and 
other algorithms in a manner similar to the CAMELYON challenges 
for breast cancer and lymph node metastasis.41,42
Another future goal could be the release of “official” Banff 
algorithms that could be used by the Banff community. These in-
clude targeted, handcrafted, or “real intelligence” algorithms for 
parameters such as fibrosis, inflammation, steatosis, and so forth. 
AI also has the potential to increase diagnostic accuracy and in-
form enrollment and outcomes in pathology-based clinical trials 
in transplantation. Eventually AI/machine learning algorithms 
that have been thoroughly benchmarked could be made available. 
Furthermore, data pipelines for the integration of “–omic” data 
could be made available so that centers could have mechanisms 
for mining data within their center as well as sharing data with 
other centers. Tools for integrating data such as natural language 
processing algorithms such as those discussed by Alexandre 
Loupy and being developed by the Paris Transplant group and 
others could eventually be distributed in the community. Of note, 
in addition to artificial intelligence, “AI” can refer to the term “aug-
mented intelligence”;43,44 and it is hoped that these technologies 
and others can help “augment” the skills of pathologists and other 
medical professions.
Economic concerns are likely relevant for many of the efforts of 
the Banff DPWG. Implementation of digital pathology can be rather 
costly, since it typically requires purchase of WSI scanners and com-
puters and infrastructure for the acquisition, storage, and delivery 
of images. Such technology requires the financial support of de-
partmental and institutional administrators, and business use case 
considerations must be addressed. Effects on workload must be 
considered, including potential redistribution of pathologist duties 
as well as the potential necessity for technicians to operate the WSI 
scanners and bioinformatics computer specialists to manage the 
data produced. In some cases, workload balancing and other factors 
could result in a return on investment. Cost considerations may also 
affect the selection of image analysis algorithms, since open source 
algorithms are essentially freely available as opposed to commercial 
algorithms that typically require financial investment for purchase 
and technical support. Because both radiology and pathology are 
subspecialties that deal with image-intensive data, some authorities 
have advocated for joint radiology/pathology programs to manage 
the large images produced by WSI scanners.27,28,45,46 For the Banff 
efforts proposed in this white paper, the working group will likely 
need to leverage the resources of departments and institutions that 
have excess capacity to support research collaboration. The Banff 
DPWG could eventually provide open source algorithms at essen-
tially no cost, and this could help alleviate some of the economic 
burden for the implementation of digital pathology.
It is striking how much simpler the issues have become be-
tween the time of the September 10, 2019, video request for 
comments on the white paper2 and the writing of this article, a 
reflection of the success of the feedback process. There is a fur-
ther simplification one can envision reading Keith Kaplan's recent 
blog posting of January 14, 2020,47 predicting the future of digital 
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pathology where everything is digital so we stop using the word 
“digital” because it is redundant. We can all sense that that day 
will come; it is only a question of when. In that sense this white 
paper is only an interim step until we reach the point where we 
no longer have to say “digital” because everyone is thinking that 
way anyway.
F I G U R E  1   General questions regarding digital pathology were asked
Question # and Question Yes [# (% answered)] No [# (%)] Skipped [#]
1. Does your pathology group 
routinely scan whole slide 
images (WSIs) for primary 
diagnosis?
Yes, we scan all of 
our pathology slides; 
and we finalize 
cases entirely from 
the digital WSIs. Our 
pathologists typically 
don’t examine the 
glass slides.
Yes, we scan 
many or all of our 
pathology slides; 
but we only sign 
out selected 
cases from the 
digital WSIs. Our 
pathologists still 
typically examine 
glass slides for 
many cases.
1 (2%) 9 (22%) 31 (76%) 1
2. Does your pathology group 
routinely scan WSIs for 
research or education?
30 (71%) 12 (29%) 0
3. Do you use commercial or 
customized digital pathology 
image analysis algorithms for 
the examination of certain 
features?
10 (25%) 30 (75%) 2
4. Do you use artificial 
intelligence/machine learning 
in the analysis of digital 
pathology images?
5 (88%) 37 (12%) 0
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F I G U R E  2   Question 5. What is your 




Pathology and Histocompatibility/ Human 
leukocyte antigen (HLA)
1 (2%)
HLA only 1 (2%)
Surgery 1 (2%)
Other Research 1 (2%)
F I G U R E  3   Question 6. What country 
do you primarily practice in?
Country # (% answered)
United States of America (USA) 23 (55%)
India 4 (10%)






Costa Rica 1 (2%)
France 1 (2%)
Belgium 1 (2%)
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F I G U R E  4   Question 7. Describe the 
current state of your digital pathology 
efforts and your view of efforts that will 
be useful to pathology in the future
# (% answered)
Still in the developing phase, not enough 
experience; currently mainly using it for 
research, will become more useful in the 
future
26 (65%)
Just got a scanner, in the process of 
validation
3 (7%)
Using it for education and research only, 
not ready for clinical use
3 (7%)
Local efforts non-existent/no resources 
available
3 (7%)
Introduced it to clinical practice/validated 3 (7%)
Memory capacity problems 1 (3%)
No scanner yet 1 (3%)
Skipped 2
F I G U R E  5   Question 8. If you are using 
artificial intelligence (AI) in the analysis 
of digital images, what programs and 
approaches are you using?
# (% answered)
Not using AI 14 (54%)
Develop their own tools/ Handcrafted 3 (11%)
For research purposes only 2 (8%)
Aperio 2 (8%)





     |  7FARRIS et Al.
Eventually, the integration of well-characterized histopathologic 
data with molecular and other data will be facilitated by efforts such 
as those being conducted by the Banff DPWG; and these efforts will 
eventually contribute to improved research, education of trainees 
and practitioners, and, importantly, patient care.
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